TABLE 1.
In vitro drug susceptibility of the Dd2attB (parental), Dd2attB::WT-pfap2-mu, and Dd2attB::160Asn-pfap2-mu transfectant strains to six antimalarial drugs
| Drug (n)a | IC50 (nM) (95% CI)b |
P valuec |
||||
|---|---|---|---|---|---|---|
| Dd2attB (parental) | Dd2attB::WT-pfap2-mu | Dd2attB::160Asn-pfap2-mu | WT vs Dd2attB | 160Asn vs Dd2attB | WT vs 160Asn | |
| Dihydroartemisinin (4) | 2.7 (2.6–2.9) | 2.5 (2.0–3.1) | 3.3 (2.9–3.8) | 0.371 | 0.0057 | 0.0227 |
| Quinine (3) | 459.2 (413.3–510.3) | 471.5 (442.1–502.9) | 671.2 (582.3–773.6) | 0.683 | <0.0001 | <0.0001 |
| Chloroquine (4) | 37.6 (25.9–54.5) | 48.0 (29.6–78.0) | 67.1 (58.6–76.8)d | 0.445 | 0.0028 | 0.1429 |
| Lumefantrine (2) | 36.1 (28.3–46.2) | 57.7 (43.0–77.4) | 44.8 (32.3–62.1) | 0.0294 | 0.3028 | 0.2517 |
| Mefloquine (6) | 13.1 (10.3–16.7) | 16.7 (13.9–19.9) | 17.0 (13.6–21.2) | 0.1416 | 0.1488 | 0.8829 |
| Atovaquone (4) | 2.7 (2.3–3.4) | 2.8 (2.3–3.5) | 4.0 (2.7–6.0) | 0.923 | 0.1014 | 0.1127 |
a
n, number of independent experiments. Each experiment had two replicates.
b
The drug sensitivity of the parasites was assessed using a classic 48-h growth inhibition assay. The best-fit curve for each drug was generated in Prism, version 6.04, and the best-fit estimate of the IC50s and their 95% confidence intervals (CIs) are indicated.
c
A sum-of-squares F test was used to test the significance of difference among the IC50s of the different parasites. The significant P values are indicated in bold.
d
For Dd2attB::160Asn-pfap2-mu, only 3 experiments with chloroquine were performed.